Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines

Adam N Pelletier, RPM Bioinfo Solutions
Rafick-Pierre Sekaly, Emory University
Jeffrey Tomalka, Emory University

Journal Title: CURRENT OPINION IN VIROLOGY
Volume: Volume 52
Publisher: ELSEVIER SCI LTD | 2022-02-01, Pages 89-101
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1016/j.coviro.2021.11.012
Permanent URL: https://pid.emory.edu/ark:/25593/vtr1

Final published version: http://dx.doi.org/10.1016/j.coviro.2021.11.012

Copyright information:
© 2021 The Author(s)
Accessed December 31, 2023 3:37 PM EST
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines

Adam N Pelletier¹, Rafick P Sekaly²,³ and Jeffrey A Tomalka²,³

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls into question how effective current SARS-CoV-2 vaccines will be moving forward. Improving on vaccine platforms represents an opportunity to stay ahead of SARS-CoV-2 and keep the human population protected. Many researchers focus on modifying delivery platforms or altering the antigen(s) presented to improve the efficacy of the vaccines. Identifying mechanisms of natural immunity that result in the control of infection and prevent poor clinical outcomes provides an alternative approach to the development of efficacious vaccines. Early and current evidence shows that SARS-CoV-2 infection is marked by potent lung inflammation and relatively diminished antiviral signaling which leads to impaired immune recognition and viral clearance, essentially making SARS-CoV-2 ‘too hot to handle’.

Addresses
¹ RPM Bioinfo Solutions, Blainville, Quebec, Canada
² Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA
³ Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA

Corresponding author:
Tomalka, Jeffrey A (jeffrey.alan.tomalka@emory.edu)

Approved SARS-CoV-2 vaccine platforms
Six COVID-19 vaccines have been approved by the WHO which span four different platforms and have efficacies ranging from 50 to 95%. The four platforms are: 1) the Moderna and Pfizer mRNA vaccines [11,12]; 2) the Johnson & Johnson human Adenovirus (AD26, COV 2.S) [13]; 3) the AstraZeneca AZD1222 chimpanzee Adenovirus (ChAdOx1 vector) vaccine [14]; and 4) the Sinopharm and Sinovac-CoronaVac inactivated virus vaccines [15,16]. The first three platforms encode for the full-length prefusion stabilized spike protein. That efficacy varies among the platforms even though the antigen is
similar, with the mRNA platforms having the highest efficacy, supporting the idea that there are specific immune pathways induced by vaccination which promote protection and vary by platform.

The development of more broadly efficacious vaccines is critical for continuing efforts to fight the SARS-CoV-2 pandemic. The emergence of variants including the delta (B.1.617.2) and omicron (B.1.1.529) variants have already begun to raise questions about the efficacy rates of current COVID-19 vaccines [17**,18,19,20**]. It has been shown that the neutralizing activity of vaccine-induced antibodies is reduced against variants including the delta, beta (B.1.351), gamma (P.1), kappa (B.1.617.1) and mu (B.1.621) variants [21–25]. Compounding this scenario is the fact that herd immunity has not been, and may never be, reached by a combination of vaccination and natural infection due to a multitude of factors including limitations on vaccine availability around the globe, the fact that high vaccine efficacy rates are benchmarked against preventing severe disease not infection/transmission, vaccine hesitations/concerns and preexisting medical conditions. Herd immunity is a population state in which a large enough percentage of individuals are immune to infection such that it nearly abrogates disease transmission between individuals thus providing protection of the whole population to the spread of disease. Common examples of vaccine-induced herd immunity are measles, mumps, and smallpox for which infections do still occur but they are not able to spread. Higher rates of infection and transmission associated with SARS-CoV-2 variants further limits the potential for herd immunity. As a result, SARS-CoV-2 viruses continue to circulate, inevitably giving rise to new variants which will further impact the efficacy of approved vaccines. This may lead to a seasonal infection similar to Influenza and the other endemic β-Coronaviruses. So where do we go from here to develop a better vaccine?

Adjuvants as a means to the end of better vaccine efficacy

Altering the antigenic component of a vaccine is not the only way to improve the efficacy of the response. The components of the vaccine platform themselves, including delivery methods, formulation, and adjuvant, can directly impact how the immune system responds to the vaccination and modulate whether or not protective responses are induced. Recent results from Arunachalam et al. showed that modifying the adjuvant included with a RBD protein subunit can modulate immune responses including Ab magnitude and breadth of variant neutralization, T cell responses and protection from viral challenge supporting the idea that inclusion of adjuvants which drive the proper protective immune responses is critical for enhancing efficacy [26**]. Similar differences in vaccine efficacy based on adjuvant inclusion were shown, specifically, for Alum and MF59 in the context of SIV/HIV [27,28*] as well as TB and Influenza [29]. This work, done by our group and others, demonstrates that Alum and MF59 induce distinct inflammatory immune profiles during vaccination which directly modulates the efficacy of vaccine responses; whether this modulation promotes or reduces vaccine efficacy is platform and pathogen dependent. That distinct adjuvants induced a different magnitude and quality of the SARS-CoV-2 (and others) vaccine response isn’t surprising, yet the expeditious nature of SARS-CoV-2 vaccine development meant no testing was performed to study the impact of adjuvants. Understanding the inflammatory pathways which drive protective COVID-19 vaccine responses and how these pathways are differentially modulated by available vaccine platforms and adjuvants is critical to the development of next generation COVID-19 vaccines. Unfortunately, the data does not currently exist to comprehensively compare the protective immune responses across the currently approved COVID-19 vaccine platforms. In the absence of such data, how can we begin to understand the key inflammatory cells and pathways important for vaccine responses to SARS-CoV-2?

Informative and relevant knowledge could be garnered from studies of an efficient natural immune response triggered upon SARS-CoV-2 infection and which would lead to the protection from dissemination of infection and from the development of poor clinical outcomes in infected subjects. Understanding the dysregulation of natural immunity during infection will provide insights into immune pathways which contribute to pathology and thus might not be effective at preventing infection. At the same time, immune pathways which are suppressed in severe cases compared to mild or asymptomatic cases could represent key targets to boost the immune response and improve vaccine efficacy. We will now discuss a critical immune mechanism associated with severe disease that can help inform on developing more efficacious vaccines.

Inflammation is a hallmark of COVID-19 disease progression

COVID-19 is characterized by progressive inflammation, lung damage, and lymphopenia which culminate in severe respiratory distress and cytokine storm in patients with severe COVID-19 disease [2,3,4**,5,6]. It has become evident that the SARS-CoV-2 virus utilizes multiple subversions of the human immune system including driving inflammation and the inhibition of the antiviral innate interferon responses [30,31]; this promotes viral persistence, mainly in individuals with pre-existing co-morbidities (age, high BMI, diabetes, etc.) or who are immunocompromised, by driving an aberrant immune response that is not capable of controlling the SARS-CoV-2 virus within the first 1–2 weeks of infection, as is normally the case for most infected individuals. Dampened interferon (IFN) responses during acute infection in
vitro and in vivo distinguish SARS-CoV-2 from other respiratory infections including Respiratory Syncytial virus (RSV) and Influenza A virus (IAV) [32**,33]. Select human clinical trials using IFN treatment have shown efficacy in reducing disease severity, disease longevity, recovery from symptoms and mortality, indicating that interferons may be critical for limiting COVID-19 disease [34–36]. This early IFN signaling is responsible for priming cells towards an anti-viral state that allows the control of viral dissemination. In the absence of a potent induction of antiviral interferons stimulated genes (ISGs), SARS-CoV-2 virus can persist in the upper and lower airway epithelium leading to infectious spread to the circulation and progressive COVID-19 disease. It is found that inflammasomes and IFNs regulate each other; inflammasomes antagonize IFN responses by cleaving cGAS to limit IFN production downstream of cGAS/STING; IFN signaling has been shown to suppress inflammasome activation in response to multiple stimuli including the adjuvant Alum [37–39]. Thus, scales tipped too far in favor of inflammation over IFN signaling could be a major contributing factor to the severity of acute infection, the subsequent down regulation of effective innate and adaptive immune responses, and disease progression. So then, what is the source of this deleterious inflammation?

Progression to severe COVID-19 is highlighted by a local and systemic inflammatory response and the subsequent degeneration of respiratory function. Evidence from SARS-CoV-2 infected patients highlight inflammasomes and IL-1β as potential critical mediators of this inflammation [5]. Inflammasomes are cytosolic, multi-protein complexes which mediate activation of inflammatory caspases and the eventual processing of pro-IL-1β and pro-IL-18 into their biologically active forms. Inflammasomes can be activated in response to a wide range of stimuli, including bacteria [40–44], fungi [45–47] and host DAMPs [48,49] as well as, to a lesser extent, viruses [50–52]. These cytokines are potent inflammatory regulators which drive leukocyte chemotaxis, activation, and differentiation. IL-1β in tissue activates potent neutrophil and macrophage responses to combat extracellular infection and cellular dysfunction caused by tissue damage [46,53–56]. In line with this, altered neutrophil and macrophage responses are hallmarks of COVID-19 lung damage and disease progression [57,58,59**,60–62]. Evidence of inflammasome activation is also present in the blood of patients with severe COVID-19 [63*,64].

Inflammasome activation also routinely induces a lytic form of cell death called pyroptosis which is mediated by cleavage of Gasdermins, canonically Gasdermin-D, and their insertion as multimeric pores into cellular membranes [65,66]. The resulting perturbation in ion homeostasis (K+ efflux and Ca2+ influx/mobilization) leads to cellular rupture and release of inflammatory components normally sequestered within the cytosol of the cell. One of these components, Lactate Dehydrogenase or LDH, is a marker for COVID-19 disease severity and progression supporting that inflammasome induced cell death is a driver of COVID-19 pathology [67,68*,69]. Heightened cell death induced by inflammasomes combined with the capacity of IL-1β to promote chemokine production and extravasation of cells into tissues could explain the acute and persistent lymphopenia observed in COVID-19 patients [70–72]. Systemically, IL-1β mediates its effects through direct binding to the cell as well as through inducing production of secondary inflammatory mediators including IL-6 and CRP [73–75], both of which have been identified as critical determinants of disease progression and severity [74,76–79]. With this mounting evidence for inflammasome signaling being a central player in COVID-19 disease progression, the next step would be to identify potential cellular sources of SARS-CoV-2-dependent inflammasome activation.

Lung inflammation spreads from epithelial cells to infiltrating cells

Given that the upper airway and lungs are the primary target of SARS-CoV-2 infection, it is logical to hypothesize that cells resident to and/or infiltrating into the lungs would be the initial source of this inflammasome activation. In vitro infection of human monocytes with SARS-CoV-2 induced inflammasome activation and cell death [63*,80]. Yet, airway epithelial cells are the main targets of natural SARS-CoV-2 infection, not monocytes.

To understand how IL-1 and inflammasome signaling is activated and spreads among the first line of immune defense, we probed publicly available datasets of single cell RNA sequencing of bronchoalveolar lavage fluid (BALF) [81**]. Liao et al. found that in severe COVID-19 disease there is heightened infiltration of macrophages and neutrophils into the BALF. To confirm these findings, we mined transcriptional profiles from the Human Cell Atlas and Human Protein Atlas to encapsulate a wider set of cells and visualize clusters using UMAP. Visual comparison of cluster frequency between healthy, mild, and severe disease shows accumulation of epithelial cells, neutrophils, and a shift in the monocyte population (Figure 1a). Quantitative assessment of frequencies of cell clusters shows significant increase in the frequency of epithelial cells within BALF from patients with severe disease compared to healthy controls and mild disease (Figure 1b). Gene Set Enrichment Analysis (GSEA) was performed to identify if IL-1 and inflammasome related pathways were being differentially modulated in the epithelial cells from severe COVID-19 as compared to mild COVID-19 and healthy controls. Indeed, we observed heightened expression of key pathways of IL-1 signaling and NF-κB inflammation in epithelial cells from severe COVID-19 compared to mild disease or healthy controls (Figure 1c). Multiple key inflammatory
Preventive and therapeutic vaccines

Figure 1

(a) 

(b) 

(c) 

(d) 

HALLMARK_TNFA_SIGNALING_VIA_NFKB in Epithelial_cells

Current Opinion in Virology
mediators (including IL-1β, CXCL1, CCL2) and transcriptional regulators (including KLF4, FOS, JUN, MYC, NFKB2, NFKBIE) were among the leading-edge genes from the Hallmark NF-κB pathway (Figure 1d). Interestingly, expression of genes in the INFLAMMATION pathway, including CASP1 which encodes for Caspase-1, are reduced in severe disease. The simultaneous heightened IL-1β/inflammatory signaling and diminished inflammasome expression in epithelial cells, normally upregulated by inflammatory signaling, suggests that epithelial cells in severe disease which express inflammasomes die; the resulting inflammatory signaling then spreads to the remaining neighboring epithelial cells.

Analysis of infiltrating leukocyte populations revealed that there were significantly elevated neutrophils in severe disease compared to mild or healthy controls (Figure 2a). Increased monocyte derived macrophages and decreased alveolar macrophages are a feature of both mild and severe disease, with severe disease showing more significant modulations (Figure 2b). Pathway analysis for inflammatory and IL-1 pathways reveals that inflammatory pathways are significantly elevated in severe versus mild disease for all subsets of monocytes/macrophages probed and neutrophils. Thus, not only are there more neutrophils and monocyte derived macrophages in severe disease but these cells are also in a heightened inflammatory status. IL-1 signaling pathway genes upregulated in neutrophils during severe disease include IL-1β itself, suggesting a potential additional source of IL-1β in vivo, early targets (IL1RN, HMGB1) and regulators of IL-1/NF-κB signaling (IL1R1, IRAK1/3, RELA, NFKB1/2, NFKBIA). In this way, severe COVID-19 disease is marked by the infiltration of circulating neutrophils and monocytes, which become macrophages, that sense the inflammation driven by IL-1 signaling in epithelial cells and become primed for inflammatory responses. These potentially activated neutrophils and macrophages can then mediate tissue damage through the production of proteases (MMPs, Elastase, etc.) which degrade extracellular components, cytokine production and cell death. Cell death releases inflammatory mediators which further exacerbate cell activation and tissue damage. Inflammation generated in the lungs can then spread to the periphery, as evidenced by previous discussion of systemic markers of inflammasome and inflammation, where a cytokine storm drives progressive dysfunction and disease severity. Inflammasome activation that is localized to the lungs and limited in the circulating blood could explain why the cytokine storm in COVID-19 does not lead to the rapid and high mortality traditionally associated with microbial sepsis. Microbial sepsis [82] is a disease where inflammasome activation and inflammation within the blood drives rapid multi-system organ failure and death in contrast to the prolonged disease course associated with the cytokine storm seen in severe COVID-19. Figure 3 provides a model of initial inflammatory signaling that is activated in the lungs in response to SARS-CoV-2, and potentially mucosal microbial dysbiosis, and spreads to the periphery, driving disease severity and eventually mortality. Thus, vaccines which include adjuvants, or vectors, that augment or exacerbate tissue inflammation as is seen in SARS-CoV-2 infection may not produce robust or effective immune responses following vaccination.

**Implications for vaccine development**

**Avoiding the bad inflammation**

So what does this mean for the development of the next generation of COVID-19 vaccines? If inflammasome and IL-1 activation do not induce protective immunity to natural infection, we may consider avoiding using vaccine components which can potentely activate the inflammasomes. Though inflammasome/IL-1 activation is often thought of only as a modulator of innate immunity, it also modulates adaptive immune function. It has been shown that inflammasome activation in vaccines can enhance CD4 polyfunctionality, T follicular helper responses and the magnitude of Ab titers [83,84]. In yellow fever virus (YFV), vaccination with YFV17D is associated with inflammasome activation which, combined with complement and interferons, leads to a broad and polyfunctional T cell and B cell response post-vaccination [85]. IL-1 and IL-18 are associated with T helper subset skewing of Th1 and Th17 responses [83,86–88]. IL-18 produced by DCs has also been shown to induce antigen-independent production of IFN-gamma from effector CD8+ T cells [89].

The licensed adjuvant Alum [90,91] is known to activate the NLRP3 inflammasome. Likewise, certain DNA viral vectors including Adenoviruses [92,93] and modified vaccinia virus Ankara (195433)80 lead to activation of inflammasomes including AIM2 [94], IFI16 and NLRP3. The widespread use of Alum as an adjuvant suggests that inflammasome activation is important for vaccine
Infiltrating neutrophils and monocytes into the lung acquire an inflammatory phenotype and dominate the local immune response to SARS-CoV-2. Using the same data as in Figure 1, we analyzed the frequency and gene expression status of immune cells in the BALF. (a) Neutrophil frequencies were significantly increased in the BALF of severe disease versus mild disease and healthy controls. Monocyte-derived macrophages were also significantly increased in severe disease versus healthy controls, with an increase also observed in mild disease. (b) We observe a concomitant loss of resident alveolar macrophages in severe and mild disease. These data suggest that infiltrating neutrophils/monocytes begin to dominate the local lung immune response during severe COVID-19. (c) GSEA analysis per cell cluster reveals a consistent signature of upregulated inflammation in immune subsets including in monocytes/macrophages, alveolar macrophages and neutrophils. (d) Leading edge genes from the IL-1 signaling pathway reveal key regulators of IL-1β/NF-κB are upregulated in infiltrating immune cells in severe COVID-19 disease. Comparison of cluster frequencies was performed using paired-Wilcoxon sum rank test.
Inflammasome and IL1 signaling spread to the lung circulation following SARS-CoV-2 infection and drive severe COVID-19 disease

Model of the induction and spread of inflammasome/IL-1β driven inflammation from the lung to the periphery in COVID-19. In Step i, SARS-CoV-2 virus infected epithelial cells and leads to intrinsic inflammasome activation and inflammatory signaling from infected epithelial cells in Step ii. This local inflammatory response promotes chemokine production and leads to the infiltration of circulating leukocytes including innate and adaptive immune cells to the lungs in Step iii. The rampant inflammatory response activates these infiltrating cells eventually leading to Step iv involving degranulation and/or cell death of immune cells further exacerbating inflammation; this process culminates in further damage to the lung tissue including epithelial cells in Step v. This inflammatory response does not remain local and spreads to the periphery causing (Step vi) cytokine storm and eventually the need for oxygen, mechanical ventilation and death in severe cases.

responses, however there is controversy concerning this subject. There are multiple publications which have published data showing that the NLRP3 inflammasome is dispensable for the adjuvant effect of Alum [95–97]. Similarly, while flagellin has been shown to be an adjuvant [98,99], it has been shown that the adjuvant activity of flagellin can be independent of NLRC4 [100,101], the inflammasome known to be activated by flagellin [100]. So while Alum is a potent adjuvant, it is far from clear how dependent this effect is on inflammasome activity. Inflammatory caspases are not the only mechanisms of activating IL-1 cytokines. There are multiple sources of proteases including neutrophils which can mediate cleavage and activation of IL-1 (reviewed in Ref. [102]).

Inflammasome activity in the context of other vaccines is also ambiguous. In influenza, it was recently shown that heightened inflammasome activation, resulting from antibiotic treatment, was associated with lower H1N1-specific neutralizing and binding IgG and IgA [103]. However in HIV/SIV, it has been shown that the canarypox vector ALVAC, a known activator of the inflammasome via AIM2 [104], promotes vaccine efficacy by inflammasome activation in monocytes NHP [105]. We have recently published that ALVAC induced CREB1 activation, a critical modulator of reduced HIV-1 acquisition in humans and protection from SIV challenge in NHP, was associated with IL-18 production which regulated pathways of immune activation in DCs [27].

In the context of SARS-CoV-2, the two approved inactivated virus vaccines, Sinopharm and Sinovac-CoronaVac, both use Alum as adjuvant and have reported lower efficacy rates than the mRNA-based vaccines from Moderna and Pfizer. A recent study used Systems Vaccinology to investigate the immune responses induced by the
Pfizer vaccine. Of pertinence, they did not observe potent or persistent inflammation post-vaccination, however they did not compare this to any other SARS-CoV-2 vaccine [106**]. It is prudent and necessary to better understand how inflammasome activation and inflammation during SARS-CoV-2 vaccination modulates vaccine efficacy and long-lived immunity. Controlled clinical studies are needed to compare Alum with other adjuvants (MF59, TLR ligands) to clearly understand the innate immune responses needed during vaccination to promote vaccine efficacy. We can learn lessons from what does and does not work for the immune response during natural infection to continue to inform vaccine development.

**Augmenting the good inflammation**

By identifying dampened Interferon antiviral responses as a hallmark of SARS-CoV-2 infection and disease, we can now envision designing vaccine regimens which potently induce IFN responses to augment the generation of cells which can combat SARS-CoV-2 infection. A recent study of Influenza vaccination identified epigenetic changes which persisted after vaccination in monocytes and DCs which were correlated with protection from subsequent viral challenge, both to homologous (same) and heterologous (different; Zika and Dengue) viruses [107**]. Another study, which used a Systems Immunology approach to dissect the immune responses generated in human to the Pfizer-BioNtech SARS-CoV-2 vaccine, showed that antiviral and IFN signaling pathways were more potently induced in monocytes and DCs after the boost (2nd dose) compared to the prime (1st dose) [106**]. Both of these studies indicate the acquisition of Trained Immunity, a newly described process whereby exposure of innate immune cells to pathogenic stimuli induces epigenetic changes which augment future innate immune responses to challenge [108–111]. This has tremendous implications for vaccine development as these heightened innate immune responses could help limit breakthrough infections in vaccinated individuals. This includes infections with viral variants as innate immune responses are antigen-independent and unlikely to be substantially impacted by mutations observed in viral variants.

Adjuvants are currently in development and pre-clinical/clinical testing which may potently induce interferon signaling including TLR agonists [112–114] and small molecule STING agonists [115–117]. We know from a recent study that inclusion of 5 distinct adjuvants in a protein subunit COVID-19 vaccine results in differential modulation of vaccine response. Specifically, 4 adjuvants targeting antiviral/interferon signaling showed efficacy while an oil-in-water formulation did not [26**]. Within the 4 successful adjuvants, there was variance in protection with all adjuvants inducing no detectable virus in the BAL but in the nares, there was no detectable viral RNA in four of five monkeys for AS37 and CpG-Alum compared to only three of five monkeys for AS37 and Alum. Different nucleic acid composition of vaccine vectors may be differentially sensed by TLRs and cytosolic sensors of nucleic acids leading to downstream differences in interferon signaling.

What we learn about the pathogenesis of SARS-CoV-2 infection can inform how the research community approaches profiling and identifying the immune correlates of protection during COVID-19 vaccination, across multiple platforms. A targeted approach to optimize the platform(s) ultimately chosen for future COVID-19 vaccines represents an opportunity to improve on the overall efficacy of vaccines, irrespective of antigen inclusion. While inflammation is a necessary component of vaccine responses, too much vaccine induced inflammation may not yield protective responses in COVID-19 vaccines. Identifying what constitutes good inflammation versus bad inflammation for SARS-CoV-2 vaccination requires controlled studies which access samples within days of vaccination and link these early signatures to long-term protection; a difficult task made even more difficult by the increasingly lower number of individuals naïve to SARS-CoV-2 infection and/or vaccination. An ideal adjuvant may be one that is capable of potently inducing interferon/antiviral responses while maintaining enough inflammation to drive chemotaxis and jump start the immune response. Identifying potential pathways ahead of time provides the opportunity to stay ahead of SARS-CoV-2 by not waiting potentially years for detailed immune analyses of current vaccine(s) to inform on vaccine design. Using available data on natural SARS-CoV-2 infection and COVID-19 disease allows us to be more proactive in designing the future of COVID-19 vaccines.

**Methods**

**Single-cell transcriptomics**

Raw count matrices for BALF single-cell RNA-seq data were extracted from SRA Archive GSE145926 and imported into the R package Seurat for preprocessing.

Cells with high mitochondrial content (>0.1 of reads) and low number of reads (<200) were filtered out for Quality Control. Expression was integrated across patients using the SCTransform approach from Seurat using 3000 genes as anchors on the basis of their high variance across cells, while an additional 4000 genes were also integrated using those same anchors. Principal component was performed on normalized integrated data, and the optimal number of components was inferred (25) using the Elbow method for clustering and UMAP dimension reduction.

SingleR was used to infer cell identity of individual clusters on the basis of the expression of their top 100 most differentially expressed genes (FindAllMarkers function, Seurat) in comparison with the Human Cell Atlas (https://
www.humancellatlas.org/) and Monaco reference profiles from the Human Protein Atlas (https://www.proteinatlas.org/). Clustered inferred with the same cell type were merged together to facilitate downstream analysis.

MAST was used to perform differential expression across severity groups, or versus viral counts/cell frequencies, by using raw counts and taking into account cellular detection rate and sample provenance as covariates.

Gene Set Enrichment Analysis (GSEA) was performed using the z score from the MAST analysis as ranking variable, and was tested against inflammasome/apoptosis genesets.

Median expression per gene/cell type/sample was computed and used for visualization purposes in heatmap format. The combined leading edge genes across contrasts was extracted on significant GSEA enrichments, and was leveraged to generate row-normalized heatmaps of pathways across cells and patients.

Authors’ contribution

ANP performed bioinformatic analysis, interpretation of results and edited the manuscript. RPS aided in interpretation of results and preparation/editing of manuscript. JAT devised the conceptual basis of the manuscript, planned bioinformatic analysis, interpreted results and drafted the manuscript.

Funding

This research was supported by NCI/NIHU54CA260563 and NIAID/NIHU19AI28910.

Conflict of interest statement

Nothing declared.

Acknowledgements

We acknowledge Vinicius Suzart for helping to generate the visual model in Figure 3 created with BioRender.com. We acknowledge Asad Abbas for helping proof the review.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

* of special interest
** of outstanding interest

1. https://ourworldindata.org/coronavirus-data.

2. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydias I, Kritas SK: Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVID-19 or SARS-CoV-2) anti-inflammatory strategies. J Biol Regul Homeost Agents 2020, 34:327-331.

3. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S et al.: Viral and host factors related to the clinical outcome of COVID-19. Nature 2020, 583:437-440.

4. Hadjadj J, Yatin N, Barnabei L, Corneau A, Bousquier J, Smith N, **Pere H, Charbit B, Bondet V, Chenevier-Gobeaux C et al.:** Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020, 369:719-724.

5. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C: Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol 2020, 11:1708.

6. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, Rech R, Colombo R, Antinori S, Corbellino M et al.: Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020, 20:1135-1140.

7. Fourati S, Tomalin LE, Mule MP, Chawla D, Gerritsen B, Ryckov D, Henrich E, Miller H, Hagain T, Diray-Arce J et al.: An innate immune activation state prior to vaccination predicts responsiveness to multiple vaccines. bioRxiv 2021.

8. Hou J, Wang S, Li D, Carpp LN, Zhang T, Liu Y, Jia M, Peng H, Liu C, Wu H et al.: Early pro-inflammatory signal and T-cell activation associate with vaccine-induced anti-vaccinia protective neutralizing antibodies. Front Immunol 2021, 12:737487.

9. Nakayama T: An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity. Vaccine 2016, 34:5815-5818.

10. Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ, Kwak LW: Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T-cell-, and not B cell-, dependent antitumor immunity. Blood 2009, 114:4142-4149.

11. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB et al.: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021, 384:403-416.

12. Polack FP, Thomas SJ, Kitchin N, Absalon J,urtman A,Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C et al.: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020, 383:2603-2615.

13. Sadosf J, Gray G, Vandeboch A, Cardenas V, Shukarev G, Grinztejn B, Goepfert PA, Tuyeres C, Fennema H, Spiessens B et al.: Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021, 384:2187-2201.

14. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bharat OE et al.: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397:99-111.

15. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou et al.: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021, 21:39-51.

16. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W et al.: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021, 21:181-192.

17. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Tomlinson S, Stowe J, Tesser E, Groves N, Dabreva G et al.: Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021, 385:585-594.

Of great importance to current events, Bernal et al. investigated the effectiveness of the BNT162b2 and ChAdOx1 vaccines against the emerging B.1.617.2 delta variant SARS-CoV-2. They show in this cohort of patients that efficacy of the BNT162b2 vaccine drops from 93.7% for the alpha variant to 86% with the delta variant. For ChAdOx1 efficacy from 74.5% for the alpha variant but only 67% for the delta variant. Efficacy after a single dose was also reduced from 48.7% to 30.7%.
study highlights that the delta variant, and likely other future variants, will more readily escape vaccine mediated protection.

18. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhartia KG et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021, 384:1885-1898.

19. Haciulescu E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 2021, 384:2212-2218.

20. Garcia-Beltran WF, Lam EC, St Denis K, Notido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MO et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 2021, 184:2523

In this study, Garcia-Beltran et al. test the efficacy of antibodies from 99 vaccinated individuals to neutralize 10 of the most common SARS-CoV-2 variants. They discover that five of these variants show potent resistance to neutralization including RBD mutants K417N/T, E484K and N501Y. Neutralization of B.1.351 variants was similar to the original SARS-CoV virus.

21. Pegu A, O’Connell S, Schmidt SD, O’Dell S, Talana CA, Lai L, Albrecht J, Anderson E, Bennett H, Corbett KS et al. Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants. bioRxiv 2021.

22. Edara VV, Pinska BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, Flowers MW, Wrammert J, Hussaini L, Ciric CR et al. Infection and vaccination-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med 2021, 385:646-666.

23. Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, Mantus G, Nyhoff LE, Adelman MW, Fineman R et al. Infection- and vacci-mine-induced neutralizing activity and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe 2021, 29:516-521.e3.

24. Messali S, Bertelli A, Campisi G, Zani A, Ciccozzi M, Caruso A, Caccuri F. A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine. J Med Virol 2021, 93:6469-6470.

25. Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of SARS-CoV-2 transmission by SARS-CoV-2 vaccines. Lancet Infect Dis 2021, 21.

26. Arunachalam PS, Walls AC, Golden N, Ayteo C, Fischinger S, Li C, Ayve P, Navarro MJ, Lai L, Edara VV et al. Adjuvanted subunit COVID-19 vaccine to induce protective immunity. Nature 2021, 594:253-258

In line with the focus of this review, Arunachalam et al. recently showed that the use of different adjuvants modulated the neutralizing and cross-neutralizing Ab responses in NHP receiving a protein subunit vaccine. The authors tested five different adjuvants: O/W 1849101, AS03, AS37, CpG1018-alum and alum. They found that all adjuvants except for O/W were able to induce neutralizing Ab titers and conferred protection from SARS-CoV-2 challenge. Adjuvant choice also impacted on the levels of cross-neutralizing antibodies functional against the B.1.351 variant. These data clearly highlight that adjuvant choice impacts on the nature, magnitude and potentially durability of COVID-19 vaccine responses.

27. Tomlak JA, Pelletier AN, Fourati S, Latif MB, Sharma A, Furr K, Carlson K, Lifton M, Gonzalez A, Wilkinson P et al. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccine. Nat Immunol 2022, 22:1294-1305.

28. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Callender M, Khosropour BF, Shen X, Tomaras GD, Billings E et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med 2016, 22:762-770

This paper is crucial in identifying that the nature of the adjuvant included in a vaccination has a profound impact on efficacy and protection. In this study, the authors show that ALVAC vaccination with the adjuvant MF59 is protective from SIV infection while ALVAC vaccination with the adjuvant MF59 is not protective. Though MF59 is itself a potent adjuvant and has been shown to enhanced humoral immune responses, in this vaccine platform its inclusion proved deleterious compared to Alum. This highlights the point that one size does not fit all when it comes to vaccines and adjuvants.

29. Knudsen Niels Peter H, Olsen Anja, Buonsante Cecilia, Follmann Frank, Zhang Coler, Rhea N, Fox Christopher B, Minke Andreas, D’Oro Ugo, Casini Daniele et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep 2016, 6.

30. Acharya D, Liu G, Gack MU: Disregulation of type I interferon responses in COVID-19. Nat Rev Immunol 2020, 20:397-398.

31. Sa Ribiero M, Jouvenet N, Drex M, Nisole S: Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog 2020, 16:e1008737.

32. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Roll R, Jordan TX, Olalke D, Panou V, Rapti V et al. Unaffected antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flux comparison. Nat Immunol 2021, 22:32-40.

33. Galani IE, Rovina N, Lampropoulou V, Triantafylla V, Manioudaki M, Pavlos E, Koukaki E, Fragkou PC, Panou V, Rapti V et al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep 2021, 11:8059.

34. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho LP et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2021, 9:196-206.

35. Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, Wang ZH, Tebbutt SJ, Kollmann TR, Fish EN: Interferon-alpha2b treatment for COVID-19. Front Immunol 2020, 11:1061.

36. Burke TP, Engstrom P, Chavez RA, Fonbuena JA, Vance RE, Welch MD: Inflammasome-mediated antagonism of type I interferon enhances Rickettsia pathogenesis. Nat Microbiol 2020, 5:688-696.

37. Wang Y, Ying X, Gao P, Wu S, Sha M, Lv M, Zhou X, Gao J, Fang R, Meng G et al.: Inflammasome activation triggers caspase-1-mediated cleavage of cGAS to regulate responses to DNA virus infection. Immunity 2017, 46:393-404.

38. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, Farlik M, Decker T, Du Pasquier RA, Romero P et al.: Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34:213-223.

39. Sha W, Mitoma H, Hanabuchi S, Bao M, Weng L, Sugimoto N, Liu Y, Zhang Z, Zhong J, Sun B et al.: Human NLRP3 inflammasome senses multiple types of bacterial RNAs. Proc Natl Acad Sci U S A 2014, 111:16059-16064.

40. Costa A, Gupta R, Signorino G, Malara A, Cardile F, Biondo C, Midiri A, Gabo R, Trieu-Cuot P, Papasergi S et al.: Activation of the NLRP3 inflammasome by group B streptococci. J Immunol 2012, 188:1953-1960.

41. Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H, Liu L, Shao F: The NLR4C inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011, 477:596-600.

42. Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozoren N, Jagirdar R, Inohara N, Vandenberghe P, Bertin J, Coyle A et al.: Cytosolic flagellin requires Iapf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 2006, 7:576-582.
44. Miao EA, Ernst RK, Dors M, Mao DP, Ademir A: *Pseudomonas aeruginosa* activates caspase 1 through Ipaf. Proc Natl Acad Sci U S A 2008, 105:2562-2567.

45. Hise AG, Tomalika J, Ganases S, Patel K, Hall BA, Brown GD, Fitzgerald KA: An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen *Candida albicans*. Cell Host Microbe 2009, 5:487-497.

46. Tomalika J, Ganases S, Azodi E, Patel K, Majmudar P, Hall BA, Fitzgerald KA, Hise AG: A novel role for the NLRC4 inflammasome in mucosal defenses against the fungal pathogen *Candida albicans*. PLoS Pathog 2011, 7:e1002379.

47. Said-Sadier N, Padilla E, Langsley G, Ojcius DM: *Aspergillus fumigatus* stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS One 2010, 5:e10008.

48. Kelley N, Jeltema D, Duan Y, He Y: The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci 2019, 20.

49. Martinon F: Signaling by ROS drives inflammasome activation. Eur J Immunol 2010, 40:616-619.

50. Lugrin J, Martinon F: The AIM2 inflammasome: sensor of pathogens and cellular perturbations. Immunol Rev 2018, 281:99-114.

51. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BK, Ganases S, Latz E et al.: The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010, 11:395-402.

52. Zhang H, Luo J, Alcorn JF, Chen K, Fan S, Pilewski J, Liu A, Chen W, Kolls JK, Wang J: AIM2 inflammasome is critical for influenza-induced lung injury and mortality. J Immunol 2017, 198:4383-4393.

53. Oliveira SH, Canetti C, Ribeiro RA, Cunha FG: Neutrophil migration induced by IL-1beta depends upon LTβ4 released by macrophages and upon TNF-alpha and IL-1beta released by mast cells. Inflammation 2008, 31:36-46.

54. Prince LR, Allen L, Jones EC, Hellewell PG, Dower SK, Whyte MK, Sabroe I: The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival. Am J Pathol 2004, 165:1819-1826.

55. Jorgensen I, Lopez JP, Laufer SA, Miao EA: IL-1beta, IL-18, and eicosanoids promote neutrophil recruitment to pore-induced intracellular traps following pyroptosis. Eur J Immunol 2016, 46:2761-2766.

56. Schenk M, Fabri M, Krutzik SR, Lee DJ, Vu DM, Sieling PA, Montoya D, Liu PT, Modlin RL: Interleukin-1beta triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to T cells. Immunology 2014, 141:174-180.

57. Yaginuddin A, Kvetys P, Kashir J: COVID-19: Role of neutrophil extracellular traps in acute lung injury. Respir Investig 2020, 58:419-420.

58. Kong M, Zhang H, Cao X, Mao X, Lu Z: Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol Infect 2020, 148:e139.

59. Vera FP, Pontelli MC, Silva CM, Toller-Kawahisa JE, de Lima M, • Nascimento DC, Schneider AH, Caetite D, Tavares LA, Paiva IM et al.: SARS-CoV-2 triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med 2020, 217 Neutrophil extracellular traps or NETs involve the release of nuclear DNA from neutrophils as a last line of defense to contain extracellular microbes. This process is highly inflammatory in nature and can promote further tissue damage. In this study, Vera et al. identify heighted levels of NETs in the plasma and tracheal aspirates of patients with COVID-19 compared to healthy controls. Heightened NETs were confirmed in lung tissue taken from autopsies of COVID-19 patients. They also show that SARS-CoV-2 virus can directly induce NET formation in healthy neutrophils and that these NETs promoted cell death of lung epithelial cells.

60. Middleton EA, He XY, Denerme F, Campbell RA, Ng D, Salvatore SP, Mostyka M, Baxter-Stolzburg A, Borzutz AC, Loda M et al.: Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020, 136:1169-1179.

61. Gomez-Rial J, Rivero-Calle I, Salas A, Martinon-Torres F: Role of monocytes/macrophages in Covid-19 pathogenesis: implications for therapy. Infect Drug Resist 2020, 13:2485-2493.

62. Otsuka R, Seino KI: Macrophage activation syndrome and COVID-19. Inflamm Regen 2020, 40:19.

63. Rodrigues TS, de Sa KSG, Ishimoto AY, Becerra A, Oliveira S, • Almeida L, Goncalves AV, Penecuillo DB, Andrade WA, Castro R et al.: Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med 2021, 218 Rodrigues et al. demonstrate that SARS-CoV-2 virus can directly activate the NLRP3 inflammasome in vitro in primary human monocytes. Further, they find evidence of activated inflammasomes in the PBMCs of COVID-19 patients. Heightened active caspase-1 and IL-1β were observed in COVID-19 patients and these measures correlated with disease severity. They confirmed their findings in lung autopsies tissue where they can also detect activated inflammasomes.

64. Theobald SJ, Simonis A, Georgomanolis T, Kreer C, Zehner M, Eisfeld HS, Albert MC, Chien J, Matosmey S, Enger F et al.: Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. EMBO Mol Med 2021, 13:e14150.

65. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, Zhuang Y, Cai T, Wang F, Shao F, Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015, 526:660-665.

66. Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Xu H, Lieberman J: Inflammasome-activated gaskemycin D causes pyroptosis by forming membrane pores. Nature 2016, 535:153-158.

67. Poggiali E, Zaino D, Immovilli P, Rovero L, Losi G, Dacressa A, Nucettedia M, Vadacca GB, Guidetti D, Vercelli A et al.: Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in COVID-19 patients. Clin Chim Acta 2020, 509:135-138.

68. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Pielbany M, • Lipi G: Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med 2020, 38:1722-1726.

This study, a cross-sectional, prospective study, found that lactate dehydrogenase (LDH) levels were significantly higher in patients with severe COVID-19 compared to those with mild or asymptomatic disease. High LDH levels were associated with a higher risk of mortality and hospitalization. These findings highlight the importance of LDH as a biomarker for assessing disease severity and guiding clinical management.

69. Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C, Song Z, Zha Y, Xue Y, Gu Q: Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY) 2020, 12:11245-11258.

70. Huang I, Pranata R: Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. Intensive Care Med 2019, 5:86.

71. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, Weng Z, Yang L: Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systematic review and meta-analysis. Int J Infect Dis 2020, 96:131-135.

72. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H: Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 2020, 5:33.

73. Ridker PM: From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atherosclerosis. Circ Res 2016, 118:145-156.

74. Cahill CM, Rogers JT: Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/ikappaB kinase alpha pathway targeting activator protein-1. J Biol Chem 2008, 283:25900-25912.
100 Preventive and therapeutic vaccines

75. Zhang D, Jiang SL, Rzewnicki D, Samole D, Kushner I: The effect of interleukin-1 on C-reactive protein expression in HepG2 cells is exerted at the transcriptional level. Biochem J 1995, 310:143-148.

76. Grifoni E, Valorani A, Cei F, Lamanna R, Gelli AMG, Ciambotti B, Vannucchi V, Moroni F, Pelagati L, Tarquini R et al.: Interleukin-6 as prognostic in patients with COVID-19. J Infect 2020, 81:452-462.

77. Ali N: Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. J Med Virol 2020, 92:2409-2411.

78. Sahu BR, Kampa RK, Padhi A, Panda AK: C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta 2020, 509:91-94.

79. Gubematorova EO, Gorkhova EA, Polinova AI, Drutskaya MS: IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev 2020, 53:13-24.

80. Ferreira AC, Soares VC, de Azevedo-Quintanilha IG, Dias S, Fintelman-Rodrigues N, Sacramento CQ, Mattos M, de Freitas CS, Temerozo JR, Teixeira L et al.: SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. Cell Death Discov 2021, 7:43.

81. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, ** Wang F et al.: Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 2020, 26:842-844.

In one of the first OMIcS datasets to be generated during the SARS-CoV-2 pandemic, Liao et al. used single cell sequencing of the bronchoalveolar lavage fluid to identify infiltrating innate immune cells including monocytes/macrophages and neutrophils as a feature of severe disease. This provided some of the first direct experimental evidence that infiltrating inflammatory innate immune cells were a key mediator of disease pathology.

82. Gyawali B, Ramakrishna K, Dharmo AS: Sepsis: the evolution in definition, pathophysiology, and management. SAGE Open Med 2019, 7:2050312119835043.

83. Seydoux E, Liang H, Dubois Cauwelaert N, Archer M, Rintala ND, Kramer R, Carter D, Fox CB, Orr MT: Effective combination adjuvants engage both TLR and inflammasome pathways to promote potent adaptive immune responses. J Immunol 2018, 201:98-112.

84. Barbet G, Sander LE, Gaswelier M, Leonardi I, Cerutti A, Iliev I, Blander JM: Sensing microbial viability through bacterial RNA amplifies T follicular helper cell and antibody responses. Immunity 2018, 48:584-598.e5.

85. Gaucher D, Thérrien R, Kettat N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR 3rd, Castro E et al.: Yellow fever vaccine induces integrated multilinear and polynucleofunctional immune responses. J Exp Med 2008, 205:3119-3131.

86. Deng J, Yu XQ, Wang PH: Inflammasome activation and Th17 responses. Mol Immunol 2019, 107:142-164.

87. Harrison OJ, Srinivasan N, Pott J, Schiering C, Krausgruber T, Ilott NE, Malay KJ: Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3(+) Treg cell function in the intestine. Mucosal Immunol 2015, 8:1226-1236.

88. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jettén AM, Tian Q et al.: Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.

89. Kupz A, Guarda G, Gebhardt T, Sander LE, Short KR, Diavatopoulos DA, Wijburg OL, Cao H, Waithman JC, Chen W et al.: NLR4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8(+) T cells. Nat Immunol 2012, 13:162-169.

90. Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA: Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminum adjuvants. Nature 2008, 453:1122-1126.

91. Li H, Willingham SB, Ting JP, Re F: Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3. J Immunol 2008, 181:17-21.

92. Danweesh M, Kamel W, Gavrilin MA, Akusjarvi G, Svensson C: Adenovirus VA RNAI blocks ASC oligomerization and inhibits NLRP3 inflammasome activation. Front Immunol 2019, 10:2791.

93. Barlan AU, Griffin TM, McGuire KA, Wiedhoff CM: Adenovirus membrane penetration activates the NLRP3 inflammasome. J Virol 2011, 85:146-155.

94. Suschak JJ, Wang S, Fitzgerald KA, Lu S: Identification of Aim2 as a sensor for DNA vaccines. J Immunol 2015, 194:630-636.

95. Oleszczynka E, Moran HB, Tynan GA, Hearnchen DH, Coutts G, Campbell M, Allan SM, Scott CJ, Lallev E: IL-1alpha and inflammasome-independent IL-1beta promote neutrophil infiltration following alum vaccination. FEBS J 2016, 283:9-24.

96. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, Marrack P: Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, 183:4403-4414.

97. Franchi L, Nunez G: The Nlrp3 inflammasome is critical for aluminum hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008, 38:2085-2089.

98. Knudsen ML, Johansson DX, Kostic L, Nordstrom EK, Tegerstedt K, Paselto A, Applequist SE, Lungberg K, Sirard JC, Liljestrom P: The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon. PLoS One 2013, 8:e65964.

99. Nystrom S, Bravo A, Falkeborn T, Devito C, Rissiek B, Johansson DX, Schroder U, Uematsu S, Akira S, Hinkula J et al.: DNA-encoded flagellin activates toll-like receptor 5 (TLR5), nod-like receptor family CARD domain-containing protein 4 (NLRC4), and acts as an epidermal, systemic, and mucosal-adjuvant. Vaccines (Basel) 2013, 1:415-443.

100. Lopez-Yglesias AH, Zhao X, Quarles EK, Lai MA, VandenBos T, Strong RK, Smith KD: Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathway. J Immunol 2014, 192:1587-1596.

101. Vijay-Kumar M, Carvalho FA, Atiken JD, Fidadara NH, Gewirtz AT: TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol 2010, 40:3528-3534.

102. Netea MG, van de Veerdonk FA, van der Meer JW, Dinarello CA, Joosten LA: Inflammasome-independent regulation of IL-1 family cytokines. Annu Rev Immunol 2015, 33:49-77.

103. Hagan T, Cortese M, Roupheal N, Boudreau C, Linde C, Maddur DS, Mas J, Wang H, Guthmiller J, Zheng NY et al.: Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell 2019, 178:1313-1328.e3.

104. Liu F, Niu Q, Fan X, Liu C, Zhang J, Wei Z, Hou W, Kanneganti TD, Robb ML, Kim JH et al.: Priming and activation of inflammasome by canarypox virus vector ALVAC via the cGAS/IFI16-STING-Type I IFN pathway and AIM2 sensor. J Immunol 2017, 199:3293-3305.

105. Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M et al.: HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(-) monocytes is associated with a decreased risk of SIVmac251 acquisition. Nat Med 2018, 24:847-856.

106. Arunachalam PS, Scott MKD, Hagan T, Li C, Feng Y, Wimmers F, ** Grigroryan L, Triasal M, Edrada VV, Lai L et al.: Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature 2021, 596:410-416.

This study is a critical source of information on the efficacious immune responses generated by the Pfizer vaccine. Using a Systems Immunology approach, the authors are able to interrogate the key aspects of immune function augmented by the vaccine, including polyfunction CD4 and CD8 T cell responses, innate immune signaling and heightened Ab titers.
107. Wimmers F, Donato M, Kuo A, Ashuach T, Gupta S, Li C, Dvorak M, Foecke MH, Chang SE, Hagan T et al.: The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell 2021, 184:3915-3935.e21

In this paper, Wimmers et al. are able to demonstrate that influenza vaccination induces not only transcriptional changes but modulates the epigenetic landscape of the vaccine, conferring long-lived changes in chromatin accessibility which impact on future responses. Importantly, they show that months after vaccination these epigenetic modifications render cells refractory to infection by both homologous and heterologous viruses. This concept of vaccine induced trained antiviral immunity represents a major mechanism that can be leveraged in vaccines, including SARS-CoV-2, to promote better efficacy and prevent future infections.

108. van der Heijden C, Noz MP, Joosten LAB, Netea MG, Riksen NP, Keating ST: Epigenetics and trained immunity. Antioxid Redox Signal 2018, 29:1023-1040.

109. Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM et al.: Defining trained immunity and its role in health and disease. Nat Rev Immunol 2020, 20:375-388.

110. Owen AM, Fults JB, Patil NK, Hernandez A, Bohannon JK: TLR agonists as mediators of trained immunity: mechanistic insight and immunotherapeutic potential to combat infection. Front Immunol 2020, 11:622614.

111. Divangahi M, Aaby P, Khader SA, Barreiro LB, Bekkering S, Chavakis T, van Crevel R, Curtis N, DiNardo AR, Dominguez-Andres J et al.: Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol 2021, 22:2-6.

112. Luchner M, Reinke S, Millic A: TLR agonists as vaccine adjuvants targeting cancer and infectious diseases. Pharmaceutics 2021, 13.

113. Kasturi SP, Rasheed MAU, Havenar-Daughton C, Pham M, Legere T, Sher ZJ, Kovalenko Y, Gumber S, Huang JY, Gottiardo R et al.: 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci Immunol 2020, 5.

114. Kuai R, Sun X, Yuan W, Ochyl LJ, Xu Y, Hassani Najafabadi A, Scheetz L, Yu MZ, Balwani I, Schwendeman A et al.: Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy. J Control Release 2018, 282:131-139.

115. Luo J, Liu XP, Xiong FF, Gao FX, YiYL, Zhang M, Chen Z, Tan WS: Enhancing immune response and heterosubtypic protection ability of inactivated H7N9 vaccine by using STING agonist as a mucosal adjuvant. Front Immunol 2019, 10:2274.

116. Junkins RD, Gallowic MD, Johnson BM, Collier MA, Watkins-Schulz R, Cheng N, David CN, McGee CE, Sempowski GD, Shterev I et al.: A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release 2018, 270:1-13.

117. Hanson MG, Crespo MP, Abraham W, Moynihan KD, Szeto GL, Chen SH, Melo MB, Mueller S, Irvine DJ: Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest 2015, 125:2532-2546.